Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
RationalLung cancer is the most common tumor worldwide, with the highest mortality rate and second highest incidence. Immunotherapy is one of the most important treatments for lung adenocarcinoma (LUAD); however, it has relatively low response rate and high incidence of adverse events. Herein, we ex...
Main Authors: | Xi-Yang Tang, Yan-Lu Xiong, Ya-Bo Zhao, Jie Yang, An-Ping Shi, Kai-Fu Zheng, Yu-Jian Liu, Chen Shu, Tao Jiang, Nan Ma, Jin-Bo Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1014053/full |
Similar Items
-
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
by: An-Ping Shi, et al.
Published: (2022-01-01) -
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
by: Wenjing Qian, et al.
Published: (2021-09-01) -
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
by: Yuzhen Qian, et al.
Published: (2024-03-01) -
Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
by: Qing Yan, et al.
Published: (2022-02-01) -
Expression of FGL1, Distribution of Tumor-Infiltrating Lymphocytes, and Their Clinical Significance in Esophageal Squamous-Cell Carcinoma
by: LIU Yao, et al.
Published: (2022-10-01)